Format

Send to

Choose Destination
BMC Endocr Disord. 2018 Aug 31;18(1):59. doi: 10.1186/s12902-018-0288-5.

A proof-of-concept study to evaluate the efficacy and safety of BTI320 on post-prandial hyperglycaemia in Chinese subjects with pre-diabetes.

Author information

1
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong. andrealuk@cuhk.edu.hk.
2
Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. andrealuk@cuhk.edu.hk.
3
Diabetes and Endocrine Research Centre, The Prince of Wales Hospital, Shatin, New Territories, Hong Kong. andrealuk@cuhk.edu.hk.
4
School of Public Health and Primary Care, The Chinese University of Hong Kong, Prince of wales Hospital, Shatin, Hong Kong.
5
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong.
6
Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
7
Boston Therapeutics Inc., 354 Merrimack Street #4, Lawrence, MA, 01843, USA.
8
Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.

Abstract

BACKGROUND:

Galactomannan(s) are plant-derived fiber shown to reduce post-prandial blood glucose by delaying intestinal absorption of carbohydrates and slowing down gastric emptying. We examined glucose-lowering effects of BTI320, a propriety fractionated mannan(s) administered as a chewable tablet before meal in a proof-of-concept study in Chinese subjects with prediabetes.

METHODS:

Sixty Chinese adults aged 18-70 years with either impaired fasting glucose, impaired glucose tolerance, or glycated haemoglobin 5.7-6.4% (39-46 mmol/mol), were randomly assigned in 2:2:1 ratio to either BTI320 8 g (high dose), BTI320 4 g (low dose) or matching-placebo three times daily before meal for 16 weeks. The primary endpoint was change in fructosamine in subjects treated with BTI320 compared with placebo from baseline to week 4. Indices of glycaemic variability based on continuous glucose monitoring (CGM) and standard meal tolerance test were explored in secondary analyses.

RESULTS:

Of 60 subjects randomized, 3 subjects discontinued study treatment prematurely. In intention-to-treat analysis, no significant differences in change in serum fructosamine between low or high dose BTI320 and placebo were observed. Using random effect models, adjusted for variability by meals, treatment with low dose BTI320 was associated with reduction in 1-h (p < 0.01), 2-h (p = 0.01) and 3-h (p = 0.02) post-prandial incremental glucose area-under-curve and post-meal maximum glucose (p = 0.03) compared with placebo. Subjects receiving low dose BTI320 had greater body weight reduction than placebo group.

CONCLUSIONS:

BTI320 did not change fructosamine levels compared with placebo. BTI320 reduced glycaemic variability based on CGM indices.

TRIAL REGISTRATION:

The study was registered at www.clinicaltrials.gov , reference number NCT02358668 (9 February 2015).

KEYWORDS:

Fructosamine; Galactomannans; Prediabetes

PMID:
30170579
PMCID:
PMC6119318
DOI:
10.1186/s12902-018-0288-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center